BOCEPREVIR, Боцепревир ,بوسيبريفير , 波普瑞韦 Part 2/2

 


……………………………………………………………….
EXTRAS,,,,,,,,,,see      http://www.allfordrugs.com/2015/08/02/boceprevir-%D0%B1%D0%BE%D1%86%D0%B5%D0%BF%D1%80%D0%B5%D0%B2%D0%B8%D1%80-%D8%A8%D9%88%D8%B3%D9%8A%D8%A8%D8%B1%D9%8A%D9%81%D9%8A%D8%B1-%E6%B3%A2%E6%99%AE%E7%91%9E%E9%9F%A6/





1H NMR GRAPH

 



 


13c nmr

13 C NMR GRAPH

WILL BE UPDATED

13C NMR PREDICT

WO2010138889A1*	28 May 2010	2 Dec 2010	Concert Pharmaceuticals, Inc.	Peptides for the treatment of hcv infections
WO2011125006A2*	31 Mar 2011	13 Oct 2011	Pfizer Inc.	Novel sultam compounds
US20110034705 *	17 Dec 2008	10 Feb 2011	Schering-Plough Corporation	Process For the Synthesis of 3- Amino-3-Cyclobuthylmethyl-2-Hydroxypropionamide or Salts Thereof

US8188137	14 Aug 2009	29 May 2012	Avila Therapeutics, Inc.	HCV protease inhibitors and uses thereof
US8524760	10 Apr 2012	3 Sep 2013	Celgene Avilomics Research, Inc.	HCV protease inhibitors and uses thereof
EP2704570A1 *	2 May 2012	12 Mar 2014	Merck Sharp & Dohme Corp.	Drug substances, pharmeceutical compositions and methods for preparing the same
WO2014061034A1*	17 Oct 2013	24 Apr 2014	Msn Laboratories Limited	Process for preparation of boceprevir and intermediates thereof

References

• 1 Kiser JJ, Burton JR, Anderson PL, Everson GT (May 2012). “Review and Management of Drug Interactions with Boceprevir and Telaprevir”. Hepatology 55 (5): 1620–8. doi:10.1002/hep.25653. PMC 3345276. PMID 22331658.
• 2
• Degertekin B, Lok AS (May 2008). “Update on viral hepatitis: 2007″. Curr. Opin. Gastroenterol. 24 (3): 306–11.doi:10.1097/MOG.0b013e3282f70285. PMID 18408458.
• 3
• Njoroge FG, Chen KX, Shih NY, Piwinski JJ (January 2008). “Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection”. Acc. Chem. Res. 41 (1): 50–9. doi:10.1021/ar700109k.PMID 18193821.
• 4
• “Boceprevir – FDA Antiviral Drugs”. FDA. FDA. April 2011. Retrieved April 2014.
• 5
• “Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL – Forbes.com” (Press release). Forbes.com. Retrieved 2008-05-19.
• 6
• “FDA Approves Merck’s VICTRELIS™ (boceprevir), First-in-Class Oral Hepatitis C Virus (HCV) Protease Inhibitor” (Press release). Merck & Co. Retrieved 2011-05-14.
• 7
• http://www.hcvadvocate.org/news/reports/EASL_2009/Advocate_EASL_2009_Coverage.htm
• 8
• Poordad, F et al. (March 2011). “Boceprevir for Untreated Chronic HCV Genotype 1 Infection”. N Engl J Med. 364 (13): 1195–206. doi:10.1056/NEJMoa1010494. PMID 21449783.
• 9
• Jensen, D (March 2011). “A New Era of Hepatitis C Therapy Begins”. N Engl J Med. 364 (13): 1272–1273.doi:10.1056/NEJMe1100829. PMID 21449791.
• 10

Bacon, B et al. (March 2011). “Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection”. N Engl J Med. 364 (13): 1207–17.doi:10.1056/NEJMoa1009482. PMC 3153125. PMID 21449784.

SYSTEMATIC (IUPAC) NAME
(1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide
CLINICAL DATA
TRADE NAMES	Victrelis
AHFS/DRUGS.COM	Consumer Drug Information
MEDLINEPLUS	a611039
LICENCE DATA	US FDA:link
PREGNANCY CATEGORY	US: X (Contraindicated)
LEGAL STATUS	US: ℞-only
ROUTES OF ADMINISTRATION	Oral
PHARMACOKINETIC DATA
PROTEIN BINDING	75% [1]
HALF-LIFE	3.4 hours [1]
IDENTIFIERS
CAS REGISTRY NUMBER	394730-60-0
ATC CODE	J05AE12
PUBCHEM	CID 10324367
CHEMSPIDER	8499830
UNII	89BT58KELH
CHEMBL	CHEMBL218394
NIAID CHEMDB	398493
CHEMICAL DATA
FORMULA	C27H45N5O5

see part 1 at.............http://orgspectroscopyint.blogspot.in/2015/08/boceprevir-part-22_1.html
////